Toll Free: 1-888-928-9744
Published: Nov, 2015 | Pages:
136 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Moderate Psoriasis - Pipeline Review, H2 2015 Summary Global Markets Direct's, 'Moderate Psoriasis - Pipeline Review, H2 2015', provides an overview of the Moderate Psoriasis's therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Moderate Psoriasis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Moderate Psoriasis and special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides a snapshot of the global therapeutic landscape of Moderate Psoriasis - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Moderate Psoriasis and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Moderate Psoriasis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Moderate Psoriasis pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Reasons To Buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Moderate Psoriasis - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Moderate Psoriasis pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents
Table of Contents 2 List of Tables 7 List of Figures 8 Introduction 9 Global Markets Direct Report Coverage 9 Moderate Psoriasis Overview 10 Therapeutics Development 11 Pipeline Products for Moderate Psoriasis - Overview 11 Moderate Psoriasis - Therapeutics under Development by Companies 12 Moderate Psoriasis - Pipeline Products Glance 14 Late Stage Products 14 Clinical Stage Products 15 Early Stage Products 16 Moderate Psoriasis - Products under Development by Companies 17 Moderate Psoriasis - Companies Involved in Therapeutics Development 19 AbGenomics International, Inc. 19 ADC Therapeutics Sarl 20 Almirall, S.A. 21 AstraZeneca Plc 22 Avexxin AS 23 Boehringer Ingelheim GmbH 24 Celgene Corporation 25 Convoy Therapeutics, Inc. 26 Crescendo Biologics Limited 27 Delenex Therapeutics AG 28 Eli Lilly and Company 29 Forward Pharma A/S 30 Galectin Therapeutics, Inc. 31 GlycoMar Limited 32 Idera Pharmaceuticals, Inc. 33 Johnson & Johnson 34 Merck KGaA 35 OPKO Health, Inc. 36 Sandoz International GmbH 37 Soligenix, Inc. 38 Sun Pharma Advanced Research Company Ltd. 39 Syntrix Biosystems, Inc. 40 Valeant Pharmaceuticals International, Inc. 41 Moderate Psoriasis - Therapeutics Assessment 42 Assessment by Monotherapy Products 42 Assessment by Combination Products 43 Assessment by Target 44 Assessment by Mechanism of Action 47 Assessment by Route of Administration 49 Assessment by Molecule Type 51 Drug Profiles 53 (halobetasol propionate + tazarotene) - Drug Profile 53 Product Description 53 Mechanism of Action 53 R&D Progress 53 AbGn-168H - Drug Profile 54 Product Description 54 Mechanism of Action 54 R&D Progress 54 adalimumab biosimilar - Drug Profile 55 Product Description 55 Mechanism of Action 55 R&D Progress 55 AKP-11 - Drug Profile 56 Product Description 56 Mechanism of Action 56 R&D Progress 56 aminopterin sodium - Drug Profile 58 Product Description 58 Mechanism of Action 58 R&D Progress 58 AVX-001 - Drug Profile 60 Product Description 60 Mechanism of Action 60 R&D Progress 60 baricitinib - Drug Profile 61 Product Description 61 Mechanism of Action 61 R&D Progress 61 BI-655066 - Drug Profile 64 Product Description 64 Mechanism of Action 64 R&D Progress 64 brodalumab - Drug Profile 65 Product Description 65 Mechanism of Action 65 R&D Progress 65 CB-001 - Drug Profile 67 Product Description 67 Mechanism of Action 67 R&D Progress 67 CC-90005 - Drug Profile 68 Product Description 68 Mechanism of Action 68 R&D Progress 68 COVA-322 - Drug Profile 69 Product Description 69 Mechanism of Action 69 R&D Progress 69 cyclosporine - Drug Profile 70 Product Description 70 Mechanism of Action 70 R&D Progress 70 dimethyl fumarate - Drug Profile 71 Product Description 71 Mechanism of Action 71 R&D Progress 71 dimethyl fumarate - Drug Profile 72 Product Description 72 Mechanism of Action 72 R&D Progress 72 DLX-105 - Drug Profile 73 Product Description 73 Mechanism of Action 73 R&D Progress 73 etanercept biosimilar - Drug Profile 75 Product Description 75 Mechanism of Action 75 R&D Progress 75 etanercept biosimilar - Drug Profile 76 Product Description 76 Mechanism of Action 76 R&D Progress 76 GLY-2028 - Drug Profile 77 Product Description 77 Mechanism of Action 77 R&D Progress 77 GRMD-02 - Drug Profile 78 Product Description 78 Mechanism of Action 78 R&D Progress 78 guselkumab - Drug Profile 81 Product Description 81 Mechanism of Action 81 R&D Progress 81 IMO-8400 - Drug Profile 84 Product Description 84 Mechanism of Action 84 R&D Progress 84 ixekizumab - Drug Profile 86 Product Description 86 Mechanism of Action 86 R&D Progress 86 lunacalcipol - Drug Profile 87 Product Description 87 Mechanism of Action 87 R&D Progress 87 M-1095 - Drug Profile 89 Product Description 89 Mechanism of Action 89 R&D Progress 89 orilotimod potassium - Drug Profile 90 Product Description 90 Mechanism of Action 90 R&D Progress 90 SGX-301 - Drug Profile 91 Product Description 91 Mechanism of Action 91 R&D Progress 91 tazarotene - Drug Profile 93 Product Description 93 Mechanism of Action 93 R&D Progress 93 tildrakizumab - Drug Profile 94 Product Description 94 Mechanism of Action 94 R&D Progress 94 toreforant tartrate - Drug Profile 95 Product Description 95 Mechanism of Action 95 R&D Progress 95 VM-101 - Drug Profile 97 Product Description 97 Mechanism of Action 97 R&D Progress 97 Moderate Psoriasis - Recent Pipeline Updates 98 Moderate Psoriasis - Dormant Projects 131 Moderate Psoriasis - Discontinued Products 132 Moderate Psoriasis - Product Development Milestones 133 Featured News & Press Releases 133 Sep 11, 2014: Delenex Announces New Clinical Data 133 Mar 28, 2012: Amgen Announces Publication Of Phase II Study Results Of Brodalumab For Treatment Of Psoriasis In New England Journal Of Medicine 133 Appendix 135 Methodology 135 Coverage 135 Secondary Research 135 Primary Research 135 Expert Panel Validation 135 Contact Us 135 Disclaimer 136
List of Tables
Number of Products under Development for Moderate Psoriasis, H2 2015 11 Number of Products under Development by Companies, H2 2015 13 Comparative Analysis by Late Stage Development, H2 2015 14 Comparative Analysis by Clinical Stage Development, H2 2015 15 Comparative Analysis by Early Stage Development, H2 2015 16 Products under Development by Companies, H2 2015 17 Products under Development by Companies, H2 2015 (Contd..1) 18 Moderate Psoriasis - Pipeline by AbGenomics International, Inc., H2 2015 19 Moderate Psoriasis - Pipeline by ADC Therapeutics Sarl, H2 2015 20 Moderate Psoriasis - Pipeline by Almirall, S.A., H2 2015 21 Moderate Psoriasis - Pipeline by AstraZeneca Plc, H2 2015 22 Moderate Psoriasis - Pipeline by Avexxin AS, H2 2015 23 Moderate Psoriasis - Pipeline by Boehringer Ingelheim GmbH, H2 2015 24 Moderate Psoriasis - Pipeline by Celgene Corporation, H2 2015 25 Moderate Psoriasis - Pipeline by Convoy Therapeutics, Inc., H2 2015 26 Moderate Psoriasis - Pipeline by Crescendo Biologics Limited, H2 2015 27 Moderate Psoriasis - Pipeline by Delenex Therapeutics AG, H2 2015 28 Moderate Psoriasis - Pipeline by Eli Lilly and Company, H2 2015 29 Moderate Psoriasis - Pipeline by Forward Pharma A/S, H2 2015 30 Moderate Psoriasis - Pipeline by Galectin Therapeutics, Inc., H2 2015 31 Moderate Psoriasis - Pipeline by GlycoMar Limited, H2 2015 32 Moderate Psoriasis - Pipeline by Idera Pharmaceuticals, Inc., H2 2015 33 Moderate Psoriasis - Pipeline by Johnson & Johnson, H2 2015 34 Moderate Psoriasis - Pipeline by Merck KGaA, H2 2015 35 Moderate Psoriasis - Pipeline by OPKO Health, Inc., H2 2015 36 Moderate Psoriasis - Pipeline by Sandoz International GmbH, H2 2015 37 Moderate Psoriasis - Pipeline by Soligenix, Inc., H2 2015 38 Moderate Psoriasis - Pipeline by Sun Pharma Advanced Research Company Ltd., H2 2015 39 Moderate Psoriasis - Pipeline by Syntrix Biosystems, Inc., H2 2015 40 Moderate Psoriasis - Pipeline by Valeant Pharmaceuticals International, Inc., H2 2015 41 Assessment by Monotherapy Products, H2 2015 42 Assessment by Combination Products, H2 2015 43 Number of Products by Stage and Target, H2 2015 45 Number of Products by Stage and Mechanism of Action, H2 2015 48 Number of Products by Stage and Route of Administration, H2 2015 50 Number of Products by Stage and Molecule Type, H2 2015 52 Moderate Psoriasis Therapeutics - Recent Pipeline Updates, H2 2015 98 Moderate Psoriasis - Dormant Projects, H2 2015 131 Moderate Psoriasis - Discontinued Products, H2 2015 132
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.